Erasca logo

Erasca

ERAS | NASDAQ
Chart Builder DCF Calculator
$15.11
-$0.55 (-3.51%)
At close: Nov 16, 2026, 4:00 PM ET
$15.11
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.51%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
28.6
-2.0 pts
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #841/1021 (Top 82%)

Key Statistics

Market Data

Market Cap $5.3B
1D Range
14.87 15.83
52W Range
2.76 22.47

Valuation (TTM)

PE -15.26
PB 5.78
EV/EBITDA -15.42

Valuation (NTM)

Forward PE N/A
Forward PEG -0.12
Price Target $21.00
Loading financial charts...

Profile

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the ...

Sector Healthcare
Industry Biotechnology
Employees 103
IPO Date Jul 16, 2021
Fiscal Year January - December

Latest News

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

17 hours ago · globenewswire.com

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

13 days ago · globenewswire.com

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Erasca to Present at Upcoming Conferences in November

14 days ago · globenewswire.com

Erasca to Present at Upcoming Conferences in November
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

1 month ago · seekingalpha.com

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

2 months ago · globenewswire.com

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

2 months ago · globenewswire.com

Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago · globenewswire.com

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

2 months ago · globenewswire.com

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

2 months ago · globenewswire.com

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$21.00
Upside
+38.98%
Buy (7)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.